At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 140 enrolled
Drug / intervention
AGN-229666drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
In Brief
A Phase 3 clinical trial evaluating AGN-229666 for Conjunctivitis, Allergic. Completed, enrolled 140 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctivitis, Allergic
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedMar 2014
Primary CompletionJul 2014
TodayJul 2026
First PostedMar 10, 2014
Enrollment StartMar 1, 2014
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.3 years ago
Interventions
AGN-229666drug
One to two drops of AGN-229666 twice daily in each eye for 10 weeks.